Maj M, Pirozzi R, Magliano L, Bartoli L
Department of Psychiatry, First Medical School, University of Naples, Italy.
Am J Psychiatry. 1998 Jan;155(1):30-5. doi: 10.1176/ajp.155.1.30.
In this prospective study, information was collected on all bipolar I patients who started lithium prophylaxis at a lithium clinic during more than 15 years.
Patients were evaluated bimonthly with standardized instruments for as long as they took lithium. Treatment surveillance conformed to internationally accepted guidelines. Five years after starting prophylaxis, each patient was contacted for a follow-up interview.
Of the 402 enrolled patients, 27.9% were no longer taking lithium at follow-up; 38.1% were taking lithium and had had at least one recurrence of the disorder; and 23.4% were taking lithium and had had no recurrence. Among patients still taking lithium whose plasma lithium levels had been below 0.5 mmol/liter on no more than 10% of checks, 88.0% had at least a 50% reduction in mean annual time spent in the hospital compared to a reference pretreatment period, and 43.0% had had no recurrence. Patients not taking lithium at follow-up had a poorer outcome than those taking lithium, but patients no longer taking any psychotropic drug did not differ from those taking lithium. Patients no longer taking lithium had had a higher frequency of psychotic features in the index episode than those still taking lithium.
The impact of lithium prophylaxis on the course of bipolar disorder is severely limited by the high dropout rate. In bipolar patients taking lithium regularly for several years, a drastic reduction of time spent in the hospital is almost the rule; these patients represent a self-selected population in which at least one group at high risk of poor outcome is under-represented.
在这项前瞻性研究中,收集了超过15年内在一家锂盐诊所开始接受锂盐预防性治疗的所有双相I型障碍患者的信息。
患者在服用锂盐期间每两个月使用标准化工具进行评估。治疗监测符合国际公认的指南。开始预防性治疗五年后,对每位患者进行随访访谈。
在402名登记患者中,27.9%在随访时不再服用锂盐;38.1%正在服用锂盐且至少有一次疾病复发;23.4%正在服用锂盐且未复发。在仍在服用锂盐且血浆锂水平在不超过10%的检查中低于0.5 mmol/L的患者中,与治疗前参考期相比,88.0%的患者平均每年住院时间至少减少50%,43.0%的患者未复发。随访时未服用锂盐的患者预后比服用锂盐的患者差,但不再服用任何精神药物的患者与服用锂盐的患者没有差异。不再服用锂盐的患者在首发发作时出现精神病性特征的频率高于仍在服用锂盐的患者。
锂盐预防性治疗对双相情感障碍病程的影响因高脱落率而受到严重限制。在长期规律服用锂盐的双相情感障碍患者中,住院时间大幅减少几乎是常态;这些患者是一个自我选择的群体,其中至少有一组预后不良的高风险人群代表性不足。